natgillin/translations-raw huggingface dataset:
Risk of atrial flutter may be increased in patients receiving class I AADs. 
Tveganje za atrijsko undulacijo je lahko pri bolnikih, ki prejemajo antiaritmike skupine I, povečano.
BRINAVESS may be available in different vial sizes [available vial sizes to be inserted locally]. 
Zdravilo BRINAVESS je lahko na voljo v vialah različnih velikosti [velikosti vial, ki so na voljo, vstavi država članica].
Only a well-qualified healthcare professional should administer BRINAVESS and should frequently monitor the patient for the duration of the infusion and for at least 15 minutes after the completion of the infusion for signs and symptoms of a sudden decrease in blood pressure or heart rate (see section 4.4). 
Zdravilo BRINAVESS lahko da samo dobro usposobljeno zdravstveno osebje, ki mora pri bolniku med infundiranjem in še vsaj 15 minut po zaključku infundiranja pogosto preveriti, če ima znake in simptome nenadnega znižanja krvnega tlaka ali srčne frekvence (glejte poglavje 4.4).
Instructions on dose calculation, preparation of the solution for infusion, and method of administration. 
Navodila za izračun odmerka, pripravo raztopine za infundiranje in način uporabe.
BRINAVESS should be administered by intravenous infusion in a monitored clinical setting appropriate for cardioversion. 
Zdravilo BRINAVESS je treba dati v intravenski infuziji v okolju, primernem za kardioverzijo.
- Alert HCP on BRINAVESS contraindications: 
- Opozorilo za zdravstveno osebje glede kontraindikacij za zdravilo BRINAVESS:
- Alert HCP about BRINAVESS special warnings and precautions in patients with, clinically meaningful valvular stenosis, hypertrophic obstructive cardiomyopathy, restrictive cardiomyopathy, or constrictive pericarditis, previously documented LVEF ≤ 35%, advanced hepatic impairment. 
- Opozorilo za zdravstveno osebje glede posebnih opozoril in previdnostnih ukrepov za zdravilo BRINAVESS pri bolnikih s klinično pomembno stenozo zaklopk, hipertrofično obstruktivno kardiomiopatijo, restriktivno kardiomiopatijo ali konstriktivnim perikarditisom, predhodno dokumentiranim iztisnim deležem levega prekata (LVEF) ≤ 35 %, z napredovalo okvaro jeter.
• Resumption or initiation of oral-maintenance antiarrhythmic therapy can be considered 2 hours after BRINAVESS administration. 
• Ponoven začetek ali uvedba peroralnega vzdrževalnega antiaritmičnega zdravljenja pride v poštev 2 uri po uporabi zdravila BRINAVESS.
• Patients with prolonged QT at baseline (uncorrected > 440 msec), or severe bradycardia, sinus node dysfunction or second degree and third degree heart block in the absence of a pacemaker. 
• Bolniki z izhodiščnim podaljšanjem QT (nekorigirani QT > 440 msec) ali s hudo bradikardijo, disfunkcijo sinusnega vozla ali srčnim blokom 2. ali 3. stopnje brez srčnega spodbujevalnika.
- Alert HCP about the need of precautions when using BRINAVESS in haemodynamically stable patients with congestive heart failure NYHA I and NYHA II and the need to monitor patients with valvular heart disease closely. 
- Opozorilo za zdravstveno osebje, da je pri uporabi zdravila BRINAVESS pri hemodinamsko stabilnih bolnikih s kongestivnim srčnim popuščanjem v razredih NYHA I in II potrebna previdnost ter da je treba bolnike z boleznijo srčnih zaklopk natančno nadzorovati.
• Use of intravenous rhythm control anti-arrhythmics (class I and class III) within 4 hours prior, as well as in the first 4 hours after, to BRINAVESS administration. 
• Uporaba intravenskih antiaritmikov za kontrolo srčnega ritma (skupine I in III) v 4 urah pred uporabo in prve 4 ure po uporabi zdravila BRINAVESS.
• BRINAVESS should be used with caution in patients on oral AADs (class I and III), due to limited experience. 
• Zdravilo BRINAVESS je treba pri bolnikih, ki prejemajo peroralne antiaritmike (skupine I in III), zaradi pomanjkanja izkušenj uporabljati previdno.
• BRINAVESS can not be recommended in patients previously administered intravenous AADs (class I and III) 4-24 hours prior to vernakalant, due to lack of data. 
• Zdravila BRINAVESS zaradi pomanjkanja podatkov ne moremo priporočiti za bolnike, ki so 4-24 ur pred vernakalantom prejeli intravenski antiaritmik (skupine I in III).
- Alert HCP for use of AADs (anti-arrhythmic drugs) prior to or after BRINAVESS. 
- Opozorilo za zdravstveno osebje glede uporabe antiaritmikov pred uporabo zdravila BRINAVESS in po njej.
- Alert HCP for adverse events, which may occur after BRINAVESS administration, including hypotension, bradycardia, atrial flutter, or ventricular arrhythmia. 
- Opozorilo za zdravstveno osebje glede neželenih učinkov, ki se lahko pojavijo po uporabi zdravila BRINAVESS, vključno s hipotenzijo, bradikardijo, atrijsko undulacijo ali prekatno motnjo srčnega ritma.
• Intravenous rhythm control AADs should not be used in the first 4 hours after BRINAVESS administration. 
• Intravenskih antiaritmikov za kontrolo srčnega ritma se v prvih 4 urah po uporabi zdravila BRINAVESS ne sme uporabljati.
The study lasted six months. 
Študija je trajala šest mesecev.
Similar results were seen in the second study after a year. 
Podobni rezultati so bili ugotovljeni po enem letu tudi v drugi študiji.
It is available as tablets (80 and 120 mg). 
Na voljo je v obliki tablet (80 in 120 mg).
The European Commission granted a marketing authorisation valid throughout the European Union for Adenuric on 21 April 2008. 
Evropska komisija je dovoljenje za promet z zdravilom Adenuric, veljavno po vsej Evropski uniji, izdala 21. aprila 2008.
These side effects were mostly mild or moderate in severity. 
Ti neželeni učinki so bili večinoma blagi ali zmerni.
The full EPAR for Adenuric can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Adenuric je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
What measures are being taken to ensure the safe and effective use of Adenuric? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Adenuric?
Adenuric should be started two days before chemotherapy and continued for at least 7 days. 
Zdravljenje z zdravilom Adenuric je treba začeti dva dni pred kemoterapijo in nadaljevati najmanj sedem dni.
This is a summary of the European public assessment report (EPAR) for Adenuric. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Adenuric.
For more information about treatment with Adenuric, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Adenuric preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
The Committee decided that Adenuric's benefits are greater than its risks and recommended that it be given marketing authorisation. 
Zato je sklenil, da so koristi zdravila Adenuric večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
A risk management plan has been developed to ensure that Adenuric is used as safely as possible. 
Za zagotovitev čim varnejše uporabe zdravila Adenuric je bil pripravljen načrt obvladovanja tveganj.
Other information about Adenuric 
Druge informacije o zdravilu Adenuric
In both studies, allopurinol was used at a dose of 300 mg once a day, except in patients with kidney problems, who took 100 mg. 
V obeh študijah so alopurinol uporabljali v odmerku 300 mg enkrat dnevno, razen pri bolnikih s težavami z ledvicami, ki so prejemali 100 mg.
Attacks of gout can still occur during the first few months of treatment, so it is recommended that patients take other medicines to prevent attacks of gout for at least the first six months of treatment with Adenuric. 
V prvih nekaj mesecih zdravljenja še vedno lahko pride do zagonov protina, zato je priporočljivo, da bolnik vsaj prvih šest mesecev zdravljenja z zdravilom Adenuric jemlje druga zdravila za njihovo preprečevanje.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Adenuric. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil to zdravilo, na podlagi česar je oblikoval mnenje za izdajo dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
What benefit has Adenuric shown during the studies? 
Kakšne koristi je zdravilo Adenuric izkazalo med študijami?
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Adenuric, including the appropriate precautions to be followed by healthcare professionals and patients. 
V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
Adenuric is a medicine that contains the active substance febuxostat. 
Adenuric je zdravilo, ki vsebuje zdravilno učinkovino febuksostat.
For the treatment of hyperuricaemia and gout, Adenuric has been studied in two main studies involving a total of 1,834 patients. 
Pri zdravljenju hiperurikemije in protina so učinkovitost zdravila Adenuric proučevali v dveh glavnih študijah, v katerih je sodelovalo skupno 1 834 bolnikov.
Patients received either Adenuric or allopurinol for 7 to 9 days. 
Bolniki so sedem do devet dni prejemali bodisi zdravilo Adenuric bodisi alopurinol.
For the treatment of long-term hyperuricaemia, the recommended dose of Adenuric is 80 mg once a day. 
Pri zdravljenju dolgotrajne hiperurikemije je priporočeni odmerek zdravila Adenuric 80 mg enkrat na dan.
In patients with blood cancer who were undergoing chemotherapy, Adenuric was as effective as allopurinol in controlling blood levels of uric acid: in 98.3 % of patients (170 out of 173) on Adenuric blood levels of uric acid normalised compared with 96 % (166 out of 173) of patients on allopurinol. 
Pri bolnikih s krvnim rakom, ki so prejemali kemoterapijo, je bilo zdravilo Adenuric enako učinkovito kot alopurinol pri uravnavanju ravni sečne kisline v krvi: pri 98,3 % bolnikov (170 bolnikov od 173), ki so prejemali zdravilo Adenuric, se je koncentracija sečne kisline v krvi normalizirala v primerjavi s 96 % bolnikov (166 bolnikov od 173), ki so prejemali alopurinol.
For the prevention and treatment of hyperuricaemia in patients undergoing chemotherapy, Adenuric has been studied in one main study involving 346 adult patients undergoing chemotherapy for blood cancer. 
V zvezi s preprečevanjem in zdravljenjem hiperurikemije pri bolnikih, ki prejemajo kemoterapijo, so zdravilo Adenuric proučevali v eni večji študiji, v kateri je sodelovalo 346 odraslih bolnikov, ki so prejemali kemoterapijo za zdravljenje krvnega raka.
The main measure of effectiveness was based on their blood uric acid levels. 
Glavno merila učinkovitosti je temeljilo na koncentraciji sečne kisline v krvi.
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom mg once a day if blood uric acid levels remain high (above 6 mg per decilitre) after two to four weeks. 
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom deciliter), odmerek povečati na 120 mg enkrat na dan.
For the full list of all side effects and restrictions with Adenuric, see the package leaflet. 
Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Adenuric glejte navodilo za uporabo.
The most commonly reported side effects with Adenuric are gout flare-ups, abnormal liver test results, diarrhoea, nausea (feeling sick), headache, rash and oedema (swelling). 
Najpogostejši neželeni učinki, o katerih so poročali pri uporabi zdravila Adenuric, so ponovni izbruhi protina, nenormalni izvidi jetrnih testov, driska, navzeja (slabost), glavobol, izpuščaji in edem (oteklina).
Adenuric is used in patients who already have signs of a build-up of crystals, including gouty arthritis (pain and inflammation in the joints) or tophi (‘stones', larger deposits of urate crystals that can cause joint and bone damage). 
Zdravilo Adenuric se uporablja pri bolnikih, ki že kažejo znake odlaganja kristalov, vključno s protinskim artritisom (bolečino in vnetjem v sklepih) ali tofi („kamni“večjimi skupki kristalov urata, ki lahko povzročijo poškodbe sklepov in kosti).
What is the risk associated with Adenuric? 
Kakšna tveganja so povezana z zdravilom Adenuric?
By reducing the production of uric acid, Adenuric can reduce levels of uric acid in the blood and keep them low, stopping crystals from building up. 
Z zmanjševanjem tvorbe sečne kisline lahko zdravilo Adenuric zniža njeno koncentracijo v krvi in jo vzdržuje na nizki ravni ter tako ustavi kopičenje kristalov.
Adenuric is also used to treat and prevent high levels of uric acid in the blood in adults with blood cancers who are on chemotherapy and at risk of tumour lysis syndrome (a complication due to the breakdown of cancer cells causing a sudden rise of uric acid in the blood which can cause damage to the kidneys). 
Zdravilo Adenuric se uporablja tudi za zdravljenje in preprečevanje visokih ravni sečne kisline v krvi pri odraslih s krvnim rakom, ki prejemajo kemoterapijo in so izpostavljeni tveganju za sindrom tumorske lize (zapletu zaradi razgradnje rakavih celic, ki povzroči skokovito povečanje sečne kisline v krvi, kar lahko privede do okvare ledvic).
The first study, carried out in 1,072 patients, compared three doses of Adenuric (80, 120 and 240 mg once a day) with placebo (a dummy treatment) and allopurinol (another medicine used to treat hyperuricaemia). 
V prvi študiji, izvedeni s 1 072 bolniki, so tri odmerke zdravila Adenuric (80, 120 in 240 mg enkrat na dan) primerjali s placebom (zdravilom brez zdravilne učinkovine) in alopurinolom (drugim zdravilom za zdravljenje hiperurikemije).
In the first study, 48% of the patients taking 80 mg Adenuric once a day (126 out of 262) and 65% of the patients taking 120 mg once a day (175 out of 269) had levels of uric acid below 6 mg/dl in the final three measurements. 
V prvi študiji je imelo 48 % bolnikov (126 bolnikov od 262), ki so prejemali 80 mg zdravila Adenuric enkrat na dan, ter 65 % bolnikov (175 bolnikov od 269), ki so prejemali 120 mg enkrat na dan, pri zadnjih treh meritvah koncentracijo sečne kisline v krvi pod 6 mg/dl.
The CHMP concluded that Adenuric was more effective than allopurinol at lowering blood uric acid levels including in patients undergoing chemotherapy , but that it could carry a greater risk of side effects affecting the heart and blood vessels. 
CHMP je zaključil, da je zdravilo Adenuric pri zniževanju koncentracije sečne kisline v krvi učinkovitejše od alopurinola, vključno pri bolnikih, ki prejemajo kemoterapijo, vendar pa lahko pomeni večje tveganje za neželene učinke, ki prizadenejo srce in ožilje.
Adenuric is used to treat adults with long-term hyperuricaemia (high levels of uric acid or ‘urate' in the blood). 
Zdravilo Adenuric se uporablja za zdravljenje odraslih z dolgotrajno hiperurikemijo (visokimi koncentracijami sečne kisline ali urata v krvi).
The active substance in Adenuric, febuxostat, reduces the formation of uric acid. 
Zdravilna učinkovina zdravila Adenuric, feboksustat, zmanjša tvorjenje sečne kisline.
This was compared with 22% of the patients taking allopurinol (60 out of 268) and none of the 134 patients taking placebo. 
V skupini, ki je prejemala alopurinol je bilo takih bolnikov 22 % (60 bolnikov od 268), v skupini, ki je prejemala placebo, pa nobeden izmed 134 bolnikov.
The main measure of effectiveness was the number of patients whose final three blood uric acid levels were below 6 mg/dl. 
Glavno merilo učinkovitosti je bilo število bolnikov, pri katerih so bile ravni sečne kisline pri zadnjih treh meritvah nižje od 6 mg/dl. Koncentracijo sečne kisline v krvi so merili vsak mesec.
Why has Adenuric been approved? 
Zakaj je bilo zdravilo Adenuric odobreno?
Rare serious hypersensitivity (allergic) reactions to Adenuric have occurred post-marketing. 
Odkar je zdravilo na trgu, so bile resne preobčutljivostne (alergijske) reakcije na zdravilo Adenuric redke.
Adenuric was more effective than allopurinol and placebo in treating hyperuricaemia by reducing blood uric acid levels. 
Zdravilo Adenuric je bilo pri zdravljenju hiperurikemije z zniževanjem koncentracije sečne kisline v krvi učinkovitejše od alopurinola in placeba.
Adenuric treatment should not be stopped if an attack of gout occurs. 
V primeru zagona protina se zdravljenje z zdravilom Adenuric ne sme prekiniti.
This usually reduces blood uric acid levels within two weeks, but the dose can be increased to 120 
To običajno zniža koncentracijo sečne kisline v krvi v dveh tednih, vendar pa je mogoče v primeru, če ostane koncentracija sečne kisline v krvi po dveh do štirih tednih visoka (nad 6 mg na
The second study compared two doses of Adenuric (80 and 120 mg once a day) with allopurinol over one year in 762 patients. 
V drugi študiji so v obdobju enega leta pri 762 bolnikih primerjali dva odmerka zdravila Adenuric (80 in 120 mg enkrat na dan) z alopurinolom.
What is Adenuric used for? 
Za kaj se zdravilo Adenuric uporablja?
What is Adenuric? 
Kaj je zdravilo Adenuric?
How has Adenuric been studied? 
Kako je bilo zdravilo Adenuric raziskano?
How does Adenuric work? 
Kako zdravilo Adenuric deluje?
How is Adenuric used? 
Kako se zdravilo Adenuric uporablja?
It may harm them, 
Na podganah,
Make sure you do the following: 
Poskrbite za naslednje:
This medicine could seriously harm your baby. 
To zdravilo lahko hudo poškoduje otroka.
Do not change your daily dose without first talking to your doctor. 
Dnevnih odmerkov ne spreminjajte, ne da bi se o tem najprej posvetovali s svojim zdravnikom.
Mild arthropathies are generally transient. 
Blage artropatije so na splošno prehodne.
Ask your doctor which method is best for you. 
Pri svojem zdravniku se pozanimajte, katera metoda je najboljša za vas.
It is very important for you to keep all of these appointments. 
Zelo pomembno je, da redno opravite vse te teste.
Date of latest renewal: 21 September 2009 
Datum zadnjega podaljšanja dovoljenje za promet: 21. september 2009
There are no adequate data from the use of deferiprone in pregnant women. 
Ni zadostnih podatkov o uporabi deferiprona pri nosečnicah.
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines, including medicines obtained without a prescription. 
Obvestite svojega zdravnika ali farmacevta, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero koli drugo zdravilo, tudi če ste ga dobili brez recepta.
Less severe episodes of neutropenia were reported in approximately 5% of patients. 
Manj hude epizode nevtropenije so bile opažene pri približno 5 % pacientov.
In some patients it may be beneficial to reduce the dose of deferiprone and then scale it back up to the former dose. 
Pri nekaterih bolnikih je koristno zmanjšati odmerek deferiprona in ga nato zopet zvišati na predhodni odmerek.
Combined use with other iron chelators 
Sočasna uporaba z drugimi kelatorji železa
Therefore, in the event of neutropenia, rechallenge is not recommended. 
Zato se v primeru nevtropenije ponovna uporaba ne priporoča.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 25 August 1999 
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Datum odobritve: 25. avgust 1999
The neutrophil count should be then monitored more frequently. 
Število nevtrofilcev je treba nato spremljati pogosteje.
• Whenever the risk management system is modified, especially as a result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached. 
• ob vsakršni spremembi sistema za obvladovanje tveganj, zlasti kadar je tovrstna sprememba posledica prejema novih informacij, ki lahko privedejo do znatne spremembe razmerja med koristmi in tveganji, ali kadar je ta sprememba posledica tega, da je bil dosežen pomemben mejnik (farmakovigilančni ali povezan z zmanjševanjem tveganja).
The Patient/Carer reminder card shall contain the following key messages: 
Opozorilna kartica za bolnika/skrbnika mora vsebovati naslednja ključna sporočila:
The elimination half-life in most patients is 2 to 3 hours. 
Pri večini bolnikov je razpolovna doba izločanja 2 do 3 ure.
− if you are HIV positive or if your liver or kidney function is severely impaired, your doctor may recommend additional tests. 
− Če ste HIV pozitivni ali če je delovanje vaših jeter ali ledvic hudo okvarjeno, vam bo zdravnik morda priporočil dodatne preiskave.
((Inside 2)) 
((2. notranja stran))
The patient should be advised to limit contact with other individuals in order to reduce the risk of infection. 
Bolniku svetujte, naj omeji stike z ljudmi in tako zmanjša tveganje za okužbo.
Non-clinical studies have been conducted in animal species including mice, rats, rabbits, dogs and monkeys. 
Neklinične študije so bile izvedene na živalih, in sicer na miših, podganah, kuncih, psih in opicah.
• To warn women of childbearing age to not become pregnant because deferiprone may seriously harm the unborn baby. 
• opozorilo za ženske v rodni dobi, da ne smejo zanositi, saj lahko deferipron resno škoduje nerojenemu otroku.
Suggested management of cases of neutropenia is outlined below. 
Predlagan postopek obravnave primerov nevtropenije je opisan spodaj.
Monitoring of plasma Zn2+ concentration, and supplementation in case of a deficiency, is recommended. 
Priporočljivo je spremljanje plazemske koncentracije Zn2+ in tudi dopolnjevanje v primeru pomanjkanja.
There are limited data available on the use of deferiprone in children between 6 and 10 years of age, and no data on deferiprone use in children under 6 years of age. 
Podatki o uporabi deferiprona pri otrocih med 6 in 10 leti so omejeni, pri otrocih, mlajših od 6 let, pa podatkov o uporabi deferiprona ni.
− if you are allergic to deferiprone or any of the other ingredients of this medicine (listed in section 6). 
− če ste alergični na deferipron ali katero koli sestavino tega zdravila (navedeno v poglavju 6);
The total daily dose should not exceed 100 mg/kg. 
Skupni dnevni odmerek ne sme preseči 100 mg/kg.
Plasma Zn2+ concentration 
Plazemske koncentracije Zn2+
Systemic exposure to the inactive 3-O-glucuronide increased with decreasing eGFR. 
Sistemska izpostavljenost neaktivnemu 3-Oglukuronidu je naraščala z zmanjševanjem eGFR.
Your doctor will also ask you to come in for tests to monitor body iron load. 
Zdravnik vas bo tudi napotil na preiskave, s katerimi bo nadzoroval obremenitev telesa z železom.
If you miss more than one dose do not take a double dose to make up for forgotten individual doses, just continue with your normal schedule. 
Če izpustite več kot en odmerek, ne vzemite dvojnega odmerka, da bi nadomestili pozabljene odmerke, ampak nadaljujte po običajnem razporedu.
FREQUENCY NOT KNOWN 
NEZNANA POGOSTOST
The product information of deferoxamine should be consulted. 
Preučiti je treba informacije o deferoksaminu.
A low white blood cell count can be associated with a serious and potentially life-threatening infection. 
Nizko število belih krvnih celic je lahko povezano s hudo in potencialno življenjsko ogrožajočo okužbo.
− increase in appetite 
- povečanje apetita
In case of overdose, close clinical supervision of the patient is required. 
V primeru prevelikega odmerjanja je potreben skrben klinični nadzor bolnika.
No cases of acute overdose have been reported. 
Ni poročil o primerih akutnega prevelikega odmerjanja.
complete, read the card carefully and carry it with you. 
Kartico odstranite, izpolnite, natančno preberite in nosite s sabo.
- History of recurrent episodes of neutropenia. 
- Anamneza ponavljajočih se epizod nevtropenije
For agranulocytosis (ANC < 0.5x109/l): 
Za agranulocitozo (ANC < 0,5x109/l)